Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers

被引:0
作者
Karin Eijkelenkamp
Thamara E. Osinga
Mirjam M. de Jong
Wim J. Sluiter
Robin P. F. Dullaart
Thera P. Links
Michiel N. Kerstens
Anouk N. A. van der Horst-Schrivers
机构
[1] University of Groningen,Department of Endocrinology and Metabolic Diseases, University Medical Center Groningen
[2] University of Groningen,Department of Clinical Genetics, University Medical Center Groningen
来源
Familial Cancer | 2017年 / 16卷
关键词
Paraganglioma; Pheochromocytoma; mutation carriers; Surveillance;
D O I
暂无
中图分类号
学科分类号
摘要
Germline mutations of the gene encoding succinate dehydrogenase subunit B (SDHB) predispose to head-and-neck-paraganglioma (HNPGL), sympathetic PGL, pheochromocytoma and renal cell carcinoma for which regular surveillance is required. SDHB-associated tumors harbor germline and somatic mutations, consistent with Knudson’s two-hit hypothesis. To assess the penetrance and optimal surveillance for different manifestations of SDHB mutation carriers. This study included all SDHB mutation carriers who were followed at the Department of Endocrinology at the University Medical Center of Groningen. Kaplan–Meier curves were used to assess the penetrance. Poisson process was used to assess the optimal age to start surveillance and intervals. Ninety-one SDHB-mutation carriers (38 men and 53 women) were included. Twenty-seven mutation carriers (30 %) had manifestations, with an overall penetrance 35 % at the age of 60 years. We calculated that optimal surveillance for HNPGL could start from an age of 27 years with an interval of 3.2 years. This study underscores the relatively low penetrance of disease in SDHB mutation carriers. Use of the Poisson approach provides a more accurate estimation of the age to initiate surveillance and length of intervals for HNPGL. These results may give rise to reconsider the current guidelines regarding the screening of these mutation carriers.
引用
收藏
页码:123 / 130
页数:7
相关论文
共 59 条
[1]  
Pillai S(2016)Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era Crit Rev Oncol Hematol 100 190-208
[2]  
Gopalan V(2001)Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma Am J Hum Genet 69 49-54
[3]  
Smith RA(2014)Current approaches and recent developments in the management of head and neck paragangliomas Endocr Rev 35 795-819
[4]  
Astuti D(2009)The approach to the patient with paraganglioma J Clin Endocrinol Metab 94 2677-2683
[5]  
Latif F(2008)Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers Clin Endocrinol (Oxf) 69 587-596
[6]  
Dallol A(2006)Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes J Clin Endocrinol Metab 91 827-836
[7]  
Taieb D(2012)Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background Cancer Genet 205 1-11
[8]  
Kaliski A(2010)Are we overestimating the penetrance of mutations in SDHB? Hum Mutat 31 761-762
[9]  
Boedeker CC(2009)Penetrance and clinical consequences of a gross SDHB deletion in a large family Clin Genet 75 354-363
[10]  
Neumann HP(2010)Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD Hum Mutat 31 41-51